Published on April 12, 2017
With new lung cancer driver mutations being discovered, will molecular testing guidelines cover them also? Meet Dr. Paul Bunn of the University of Colorado. Dr. Bunn has dedicated his entire career to researching novel therapies for lung cancer patients. Having recently returned from the 17th Annual IASLC Targeted Therapy Meeting, Dr. Bunn shares his insights into the latest changes in molecular testing guidelines.
Produced by Patient Power and Antidote in association with the Precision Medicine for Me Initiative.